Literature DB >> 23010635

Protocoled resuscitation and the prevention of acute kidney injury.

Nicola Brienza1, Maria Teresa Giglio, Lidia Dalfino.   

Abstract

PURPOSE OF REVIEW: Acute kidney injury (AKI) occurrence in critically ill patients is common and is associated with a substantial increase in morbidity and mortality. The scope of this review is to summarize the most recent evidence-based knowledge for prevention of AKI. RECENT
FINDINGS: Recent recommendations for prevention of AKI in ICU patients are all 'negative' and, similarly, the most recent and updated guidelines about major topic areas of interest for AKI, including definition and classification, prevention, and pharmacologic treatment, have failed to identify single evidence-based recommendations for prevention and treatment of AKI. Therefore, the evaluation and management of AKI should be guided by clinical algorithms aiming to protocolized hemodynamic optimization, metabolic control, monitoring of intra-abdominal hypertension, use of diuretics to control fluid overload, and careful management of nephrotoxic factors.
SUMMARY: Key components of optimal AKI prevention include maintenance of renal perfusion and avoidance of precipitating factors. Adequate renal blood flow maintenance is the first strategy to employ not only to assure renal oxygenation, but also to prevent nephrotoxic drugs-associated AKI. Many potential therapies and interventions are on the horizon, but most of the future research will need to focus more on a step-wise, protocoled, kidney-oriented approach, than on single treatments.

Entities:  

Mesh:

Year:  2012        PMID: 23010635     DOI: 10.1097/MCC.0b013e32835944d6

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  8 in total

1.  Low Systemic Oxygen Delivery and BP and Risk of Progression of Early AKI.

Authors:  Mario Raimundo; Siobhan Crichton; Yadullah Syed; Jonathan R Martin; Richard Beale; David Treacher; Marlies Ostermann
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-24       Impact factor: 8.237

2.  Effect of goal-directed fluid therapy on renal function in critically ill patients: a systematic review and meta-analysis.

Authors:  Cong-Cong Zhao; Yan Ye; Zhi-Qiang Li; Xin-Hui Wu; Chai Zhao; Zhen-Jie Hu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

3.  Diuretic response to colloid and crystalloid fluid loading in critically ill patients.

Authors:  Annemieke Smorenberg; A B Johan Groeneveld
Journal:  J Nephrol       Date:  2014-05-15       Impact factor: 3.902

4.  Evaluation of Urinary NGAL as a Diagnostic Tool for Acute Kidney Injury in Critically Ill Patients With Infection: An Original Study.

Authors:  Brenno Cardoso Gomes; João Manoel Silva Júnior; Felipe Francisco Tuon
Journal:  Can J Kidney Health Dis       Date:  2020-06-19

5.  Impact on Outcomes across KDIGO-2012 AKI Criteria According to Baseline Renal Function.

Authors:  Isabel Acosta-Ochoa; Juan Bustamante-Munguira; Alicia Mendiluce-Herrero; Jesús Bustamante-Bustamante; Armando Coca-Rojo
Journal:  J Clin Med       Date:  2019-08-28       Impact factor: 4.241

6.  Physiologic and hemodynamic changes in patients undergoing open abdominal cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Myoung Hwa Kim; Young Chul Yoo; Sun Joon Bai; Kang-Young Lee; Nayeon Kim; Ki Young Lee
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

7.  Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience.

Authors:  Marie-Elisabeth Kajdi; Beatrice Beck-Schimmer; Ulrike Held; Reto Kofmehl; Kuno Lehmann; Michael Thomas Ganter
Journal:  World J Surg Oncol       Date:  2014-05-01       Impact factor: 2.754

8.  Predictive value of the RIFLE urine output criteria on contrast-induced nephropathy in critically ill patients.

Authors:  Aldjia Hocine; Pierre Defrance; Jacques Lalmand; Christian Delcour; Patrick Biston; Michaël Piagnerelli
Journal:  BMC Nephrol       Date:  2016-03-28       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.